Antiestrogens: Mechanisms and actions in target cells

Benita S Katzenellenbogen, Monica M. Montano, Pascale Le Goff, David J. Schodin, W. Lee Kraus, Bhavna Bhardwaj, Nariaki Fujimoto

Research output: Contribution to journalArticle

Abstract

Antiestrogens, acting via the estrogen receptor (ER) evoke conformational changes in the ER and inhibit the effects of estrogens as well as exerting anti-growth factor activities. Although the binding of estrogens and antiestrogens is mutually competitive, studies with ER mutants indicate that some of the contact sites of estrogens and antiestrogens are likely different. Some mutations in the hormone-binding domain of the ER and deletions of C-terminal regions result in ligand discrimination mutants, i.e. receptors that are differentially altered in their ability to bind and/or mediate the actions of estrogens vs antiestrogens. Studies in a variety of cell lines and with different promoters indicate marked cell context- and promoter-dependence in the actions of antiestrogens and variant ERs. In several cell systems, estrogens and protein kinase activators such as cAMP synergize to enhance the transcriptional activity of the ER in a promoter-specific manner. In addition, cAMP changes the agonist/antagonist balance of tamoxifen-like antiestrogens, increasing their agonistic activity and reducing their efficacy in reversing estrogen actions. Estrogens, and antiestrogens to a lesser extent, as well as protein kinase activators and growth factors increase phosphorylation of the ER and/or proteins involved in the ER-specific response pathway. These changes in phosphorylation alter the biological effectiveness of the ER. Multiple interactions among different cellular signal transduction systems are involved in the regulation of cell proliferation and gene expression by estrogens and antiestrogens.

Original languageEnglish (US)
Pages (from-to)387-393
Number of pages7
JournalJournal of Steroid Biochemistry and Molecular Biology
Volume53
Issue number1-6
DOIs
StatePublished - Jun 1995

Fingerprint

Estrogen Receptor Modulators
Estrogen Receptors
Estrogens
Phosphorylation
Protein Kinases
Intercellular Signaling Peptides and Proteins
Signal transduction
Cell proliferation
Tamoxifen
Gene expression
Signal Transduction
Cells
Cell Proliferation
Hormones
Ligands
Gene Expression
Cell Line
Mutation

ASJC Scopus subject areas

  • Endocrinology, Diabetes and Metabolism
  • Biochemistry
  • Molecular Medicine
  • Molecular Biology
  • Endocrinology
  • Clinical Biochemistry
  • Cell Biology

Cite this

Katzenellenbogen, B. S., Montano, M. M., Le Goff, P., Schodin, D. J., Kraus, W. L., Bhardwaj, B., & Fujimoto, N. (1995). Antiestrogens: Mechanisms and actions in target cells. Journal of Steroid Biochemistry and Molecular Biology, 53(1-6), 387-393. https://doi.org/10.1016/0960-0760(95)00084-D

Antiestrogens : Mechanisms and actions in target cells. / Katzenellenbogen, Benita S; Montano, Monica M.; Le Goff, Pascale; Schodin, David J.; Kraus, W. Lee; Bhardwaj, Bhavna; Fujimoto, Nariaki.

In: Journal of Steroid Biochemistry and Molecular Biology, Vol. 53, No. 1-6, 06.1995, p. 387-393.

Research output: Contribution to journalArticle

Katzenellenbogen, BS, Montano, MM, Le Goff, P, Schodin, DJ, Kraus, WL, Bhardwaj, B & Fujimoto, N 1995, 'Antiestrogens: Mechanisms and actions in target cells', Journal of Steroid Biochemistry and Molecular Biology, vol. 53, no. 1-6, pp. 387-393. https://doi.org/10.1016/0960-0760(95)00084-D
Katzenellenbogen, Benita S ; Montano, Monica M. ; Le Goff, Pascale ; Schodin, David J. ; Kraus, W. Lee ; Bhardwaj, Bhavna ; Fujimoto, Nariaki. / Antiestrogens : Mechanisms and actions in target cells. In: Journal of Steroid Biochemistry and Molecular Biology. 1995 ; Vol. 53, No. 1-6. pp. 387-393.
@article{94c2d0f781444030bcac5ae1d12bc440,
title = "Antiestrogens: Mechanisms and actions in target cells",
abstract = "Antiestrogens, acting via the estrogen receptor (ER) evoke conformational changes in the ER and inhibit the effects of estrogens as well as exerting anti-growth factor activities. Although the binding of estrogens and antiestrogens is mutually competitive, studies with ER mutants indicate that some of the contact sites of estrogens and antiestrogens are likely different. Some mutations in the hormone-binding domain of the ER and deletions of C-terminal regions result in ligand discrimination mutants, i.e. receptors that are differentially altered in their ability to bind and/or mediate the actions of estrogens vs antiestrogens. Studies in a variety of cell lines and with different promoters indicate marked cell context- and promoter-dependence in the actions of antiestrogens and variant ERs. In several cell systems, estrogens and protein kinase activators such as cAMP synergize to enhance the transcriptional activity of the ER in a promoter-specific manner. In addition, cAMP changes the agonist/antagonist balance of tamoxifen-like antiestrogens, increasing their agonistic activity and reducing their efficacy in reversing estrogen actions. Estrogens, and antiestrogens to a lesser extent, as well as protein kinase activators and growth factors increase phosphorylation of the ER and/or proteins involved in the ER-specific response pathway. These changes in phosphorylation alter the biological effectiveness of the ER. Multiple interactions among different cellular signal transduction systems are involved in the regulation of cell proliferation and gene expression by estrogens and antiestrogens.",
author = "Katzenellenbogen, {Benita S} and Montano, {Monica M.} and {Le Goff}, Pascale and Schodin, {David J.} and Kraus, {W. Lee} and Bhavna Bhardwaj and Nariaki Fujimoto",
year = "1995",
month = "6",
doi = "10.1016/0960-0760(95)00084-D",
language = "English (US)",
volume = "53",
pages = "387--393",
journal = "Journal of Steroid Biochemistry and Molecular Biology",
issn = "0960-0760",
publisher = "Elsevier Limited",
number = "1-6",

}

TY - JOUR

T1 - Antiestrogens

T2 - Mechanisms and actions in target cells

AU - Katzenellenbogen, Benita S

AU - Montano, Monica M.

AU - Le Goff, Pascale

AU - Schodin, David J.

AU - Kraus, W. Lee

AU - Bhardwaj, Bhavna

AU - Fujimoto, Nariaki

PY - 1995/6

Y1 - 1995/6

N2 - Antiestrogens, acting via the estrogen receptor (ER) evoke conformational changes in the ER and inhibit the effects of estrogens as well as exerting anti-growth factor activities. Although the binding of estrogens and antiestrogens is mutually competitive, studies with ER mutants indicate that some of the contact sites of estrogens and antiestrogens are likely different. Some mutations in the hormone-binding domain of the ER and deletions of C-terminal regions result in ligand discrimination mutants, i.e. receptors that are differentially altered in their ability to bind and/or mediate the actions of estrogens vs antiestrogens. Studies in a variety of cell lines and with different promoters indicate marked cell context- and promoter-dependence in the actions of antiestrogens and variant ERs. In several cell systems, estrogens and protein kinase activators such as cAMP synergize to enhance the transcriptional activity of the ER in a promoter-specific manner. In addition, cAMP changes the agonist/antagonist balance of tamoxifen-like antiestrogens, increasing their agonistic activity and reducing their efficacy in reversing estrogen actions. Estrogens, and antiestrogens to a lesser extent, as well as protein kinase activators and growth factors increase phosphorylation of the ER and/or proteins involved in the ER-specific response pathway. These changes in phosphorylation alter the biological effectiveness of the ER. Multiple interactions among different cellular signal transduction systems are involved in the regulation of cell proliferation and gene expression by estrogens and antiestrogens.

AB - Antiestrogens, acting via the estrogen receptor (ER) evoke conformational changes in the ER and inhibit the effects of estrogens as well as exerting anti-growth factor activities. Although the binding of estrogens and antiestrogens is mutually competitive, studies with ER mutants indicate that some of the contact sites of estrogens and antiestrogens are likely different. Some mutations in the hormone-binding domain of the ER and deletions of C-terminal regions result in ligand discrimination mutants, i.e. receptors that are differentially altered in their ability to bind and/or mediate the actions of estrogens vs antiestrogens. Studies in a variety of cell lines and with different promoters indicate marked cell context- and promoter-dependence in the actions of antiestrogens and variant ERs. In several cell systems, estrogens and protein kinase activators such as cAMP synergize to enhance the transcriptional activity of the ER in a promoter-specific manner. In addition, cAMP changes the agonist/antagonist balance of tamoxifen-like antiestrogens, increasing their agonistic activity and reducing their efficacy in reversing estrogen actions. Estrogens, and antiestrogens to a lesser extent, as well as protein kinase activators and growth factors increase phosphorylation of the ER and/or proteins involved in the ER-specific response pathway. These changes in phosphorylation alter the biological effectiveness of the ER. Multiple interactions among different cellular signal transduction systems are involved in the regulation of cell proliferation and gene expression by estrogens and antiestrogens.

UR - http://www.scopus.com/inward/record.url?scp=0029078487&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0029078487&partnerID=8YFLogxK

U2 - 10.1016/0960-0760(95)00084-D

DO - 10.1016/0960-0760(95)00084-D

M3 - Article

C2 - 7626486

AN - SCOPUS:0029078487

VL - 53

SP - 387

EP - 393

JO - Journal of Steroid Biochemistry and Molecular Biology

JF - Journal of Steroid Biochemistry and Molecular Biology

SN - 0960-0760

IS - 1-6

ER -